03.09.20
WIRB-Copernicus IRB has launched a new program to support initiation of protocols associated with mitigating the global spread of coronavirus.
WIRB-Copernicus IRB will give prioritized review to clinical trial protocols for COVID-19 (coronavirus) prophylactic or therapeutic vaccines and therapeutic agents, conducted under an investigational new drug (IND) application. WIRB-Copernicus IRB will also waive the initial protocol review fees for that research. To qualify for this new program, the COVID-19 protocol must be submitted before Sept. 1, 2020.
“Time is of the essence. We need to support healthcare researchers in their efforts to discover effective mediations and vaccines to treat and protect global citizens from this new coronavirus, COVID-19,” said Donald A. Deieso, PhD, Executive Chairman and CEO of WCG. “Our WCG staff want to put their skills to optimal use and play an active role in helping to address this global healthcare crisis. Through this new IRB prioritization program, we can expedite the start-up of clinical trials for COVID-19 vaccines and therapies while still maintaining the highest quality and ethical review standards.”
Interested parties should contact Amy Hutnik at ahutnik@wcgclinical.com.
WIRB-Copernicus IRB will give prioritized review to clinical trial protocols for COVID-19 (coronavirus) prophylactic or therapeutic vaccines and therapeutic agents, conducted under an investigational new drug (IND) application. WIRB-Copernicus IRB will also waive the initial protocol review fees for that research. To qualify for this new program, the COVID-19 protocol must be submitted before Sept. 1, 2020.
“Time is of the essence. We need to support healthcare researchers in their efforts to discover effective mediations and vaccines to treat and protect global citizens from this new coronavirus, COVID-19,” said Donald A. Deieso, PhD, Executive Chairman and CEO of WCG. “Our WCG staff want to put their skills to optimal use and play an active role in helping to address this global healthcare crisis. Through this new IRB prioritization program, we can expedite the start-up of clinical trials for COVID-19 vaccines and therapies while still maintaining the highest quality and ethical review standards.”
Interested parties should contact Amy Hutnik at ahutnik@wcgclinical.com.